Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types-Reference-Cited by-同舟云学术

Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types

Published:2022-01 Issue:1 Volume:55 Page:56-64.e4
ISSN:1074-7613
Container-title:Immunity
language:en
Short-container-title:Immunity

Author:

Chhibber Aparna^ORCID,Huang Lingkang,Zhang Hong^ORCID,Xu Jialin,Cristescu Razvan,Liu Xiaoqiao,Mehrotra Devan V.,Shen Judong^ORCID,Shaw Peter M.,Hellmann Matthew D.^ORCID,Snyder Alexandra

Funder

Damon Runyon Cancer Research Foundation

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference53 articles.

1. A global reference for human genetic variation;Auton;Nature,2015

2. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study;Adams;Ann. Oncol.,2019

3. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study;Adams;Ann. Oncol.,2019

4. Multimodal genomic features predict the outcome of immune checkpoint blockade in non-small-cell lung cancer;Anagnostou;Nat. Cancer,2020

5. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study;Balar;Lancet Oncol,2017

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy;Cancers;2024-09-07

2. Human leukocyte antigen evolutionary divergence as a novel risk factor for donor selection in acute lymphoblastic leukemia patients undergoing haploidentical hematopoietic stem cell transplantation;Frontiers in Immunology;2024-08-19

3. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities;Annals of Oncology;2024-06

4. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer;Briefings in Bioinformatics;2024-03-27

5. The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study;Prostate Cancer and Prostatic Diseases;2024-02-17